Company Participants Bruce Jackson - The Benchmark Company And now I'd like to introduce your host for today's program, Dave Sirois, Director of SEC Reportings. Please go ahead, sir. I will now turn the call over to Jim. Jim, please go ahead. Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Conference Call Participants Thank you for standing by and welcome to the Harvard Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorpo ...

Company Participants Conference Call Participants Operator I would now like to hand the call over to your host, David Sirois, Director of SEC Reporting. Please go ahead. Before I turn the call over to Jim, I will read our Safe Harbor statement. In our discussion today, we may make statements that constitute forward-looking statements. Our actual results and performance may differ materially from what we have projected due to risks and uncertainties, including those described in our annual report on Form 10- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorp ...

Thank you. And I'm showing no further questions at this time. I would now like to turn the call back over to Jim Green for closing remarks. James Green Okay. Well, thank you for joining us. This ends today's presentation. We hope you'll join us in the summer for our second quarter results for fiscal 2023. Thank you. And this ends the presentation. Operator And this concludes today's conference call. Thank you for participating. You may now disconnect. would be expansion of existing products that includes bo ...

FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 ___________________________ HARVARD BIOSCIENCE, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction o ...

Company Participants Operator Dave Sirois Leading the call today will be Jim Green, Chairman of the Board, President and Chief Executive Officer; and Jennifer Cote, Interim Chief Financial Officer. The difference between our GAAP and non-GAAP results are outlined in the earnings release and today's presentation. These two documents as well as a replay of this call can be found on our website under Investor Overview Events and Presentations. Additionally any material financial or other statistical informatio ...

NASDAQ: HBIO Q4'22 Earnings Presentation The non-GAAP financial information provided in this presentation should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies' non-GAAP financial information. 3 "Organizational restructuring complete and setup for success in 2023!" Q4 New Product Launches Drive Growth, Expand Financial Section 7 For FY2023, we expect: ▪ Reduce debt leverage to ~ 2X leve ...

HBIO Overview to Investors NASDAQ: HBIO Q3'22 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO November 8, 2022 HB Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Sirois - Director, Corporate Accounting & SEC Reporting James Green - President, CEO & Chairman Michael Rossi - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Bruce Jackson - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Harvard Bioscience Third Quarter 2022 Earnings Call. [Operator Instructions]. Please be advised tha ...